An update on the safety of long-acting β-agonists in asthma patients using inhaled corticosteroids

Abstract

Importance of the field: Pooled trial data have shown that long-acting β-agonists increase the risk for asthma hospitalizations and deaths by two to fourfold compared with placebo. Until recently, it was unclear whether concomitant inhaled corticosteroids (ICSs) could eliminate this risk.Areas covered in this review: This review summarizes the available data on the safety of long-acting β-agonist use in asthma, with and without concomitant ICSs. The results from an updated meta-analysis are presented, with data through December 2008.What the reader will gain: In pooled trial data, catastrophic asthma events (defined as asthma-related intubation or death) were increased fourfold for concomitant treatment with long-acting β-agonists and ICSs compared with corticosteroids alone (odds ratio 3.7; 95% CI 1.4 – 9.6). It is estimated that the addition of long-acting β-agonists to ICS therapy is associated with an absolute increase of one catastrophic event per 1500 patient-years.Take home message: When the available trial data are pooled together, it is clear that long-acting β-agonists significantly increase the risk for asthma-related intubations and deaths, even when used in a controlled fashion with concomitant ICSs. Clinical guidelines should readdress the role long-acting β-agonists have in the management of asthma.